- RSI is at a high level of 70. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 0.4. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Novo Nordisk (NVO) submits a label expansion application to the FDA for the existing marketing authorization for Ozempic to include a new dose of 2.0 mg.
Cocrystal (COCP) completes all research obligations under the Merck exclusive worldwide license and collaboration agreement.
Bausch Health (BHC) and Novaliq GmbH complete enrollment in first of the two phase III studies evaluating NOV03 to treat the signs and symptoms of Dry eye disease associated with MGD.
It's been a stellar week for Acorda Therapeutics (ACOR) investors. The stock skyrocketed over 60% after the company announced it is selling its manufacturing operations for Inbrija - Acorda’s FDA approved treatment of OFF episodes in Parkinson's disease - which should also reduce its headcount by 16%. The company’s 90,000 square-foot, FDA-inspected CGMP facility in Chelsea, Massachusetts, is being sold off to Catalent, along with the facility’s employees. The net proceeds from the deal will pock...
Acorda (ACOR) inks an agreement to sell its Inbrija manufacturing operations in Chelsea for $80 million to Catalent. The company also announces a corporate restructuring plan to save costs. Shares up.
Companies in the news are: ACOR, FRSX, GMLP, WIMI
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) * AbbVie Inc (NYSE: ABBV) * AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) * Aldeyra Therapeutics Inc (NASDAQ: ALDX) * Alkermes Plc (NASDAQ: ALKS) * AtriCure Inc. (NASDAQ: ATRC) * Bioanalytical Systems, Inc. (NASDAQ: BASI) * BIOLASE Inc (NASDAQ: BIOL) (announced an agreement to expand laser adoption and hands-on training programs in targeted geograp...
Shares of Acorda Therapeutics (NASDAQ:ACOR) moved higher by 2.42% in the past three months. Before having a look at the importance of debt, let us look at how much debt Acorda Therapeutics has.Acorda Therapeutics's Debt Based on Acorda Therapeutics's financial statement as of November 6, 2020, long-term debt is at $161.60 million and current debt is at $68.05 million, amounting to $229.65 million in total debt. Adjusted for $57.91 million in cash-equivalents, the company's net debt is at $171.74...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has entered into a definitive agreement to sell its INBRIJA manufacturing operations in Chelsea, Massachusetts to Catalent for $80 million in cash. In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda, ensuring an uninterrupted drug supply for Acorda’s patients and continued adherence to best-in-class manufacturing...